Worm M, Simpson EL, Thaçi D, et al. - In this randomized, double-blind, phase 3 clinical trial [The Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (LIBERTY AD SOLO-CONTINUE)] involving 422 patients (mean [SD] age, 38.2 [14.5] years; 227 [53.8%] male), researchers tested the safety and effectiveness of different dupilumab regimens in maintaining response after 16 weeks of initial treatment. High-responding individuals treated with dupilumab in SOLO have been rerandomized 2:1:1:1 to continue their original regimen of dupilumab, 300 mg, weekly or every 2 weeks or to receive dupilumab, 300 mg, every 4 or 8 weeks or placebo for 36 weeks. The authors discovered that continued response over time was most consistent with weekly or every 2 weeks of dupilumab administration. For both continuous and categorical endpoints, longer dosage intervals and placebo resulted in a diminution of response. There have been no new safety signals. For long-term treatment, the approved regimen of 300 mg of dupilumab every 2 weeks is suggested.